Title : A new approach based on glycyrrhizic acid for allergen delivery in allergen-specific therapy
The most effective method of treating allergic diseases is allergen-specific immunotherapy (SIT). To reduce the risk of side effects and improve the delivery of allergens to the mucosa, various delivery systems such as liposomes, dendrimers, nanoparticles, etc. can be used. Today, there is a lot of data about delivery systems based on glycyrrhizic acid (GA) and its derivatives, but these delivery systems have not yet been used for allergen-specific therapy. At the same time, GA has been shown to have anti-inflammatory effects and is itself a potential treatment for allergic bronchial asthma and allergic rhinitis. GA can shift the balance towards Th1, and increase the number of Treg cells, which means that in the future it is able to enhance the anti-allergic effect of SIT and reduce the risk of side effects. We have studied in our work the effect of the GA supramolecular complex and the allergen of house dust mite Der p 1 on the T lymphocytes and dendritic cells of patients with sensitization and doctor-diagnosed allergy to house dust mite allergen. It was found that the complex of GA and Der p1 increased the number of Treg cells in PBMCs compared to free Der p 1. Also, GA-Der p1 complex affects the inflammatory and Th2 cytokine production. The results of assessing the effect of the GA complex with Der p 1 on the phenotypic characteristics and cytokine production of cells from patients indicate a change in the Th1/Th2 balance towards the cellular immune response, an increase in the number of T-regulatory cells, which can enhance the efficiency of the Der p 1peptide during AIT. The results of evaluating the effect of the GA complex with Der p 1 on the phenotypic and functional characteristics of immune cells indicate a change in the Th1/Th2 balance towards the cellular immune response and an increase in the proportion of T-regulatory cells, which can increase the efficiency of the Der p1 peptide during SIT.